Super-resolution imaging pinpoints ultrastructural changes at the node of Ranvier in patients with polyneuropathy

Abstract

The peripheral node of Ranvier is the key element in saltatory conduction along myelinated axons, but its ultrastructural protein arrangement and interactions remain elusive in humans. To assess both physiological protein arrangement and pathological ultrastructural changes at the aranodal region of the node of Ranvier, we implement the super resolution microscopy method “direct Stochastic Optical Reconstruction Microscopy” (dSTORM) assisted by high-content confocal microscopy on nerve biopsies of patients with polyneuropathies. We demonstrate that a ∼190nm periodic arrangement of axonal cytoskeletal proteins is conserved in humans, but impaired at the paranode in polyneuropathy. In patients with polyneuropathy, the periodic protein distances of the paranodal adhesion molecules Caspr-1 and neurofascin-155 were severely elongated, implying a lateral decoiling and partial loss of the axoglial complex at the node of Ranvier. Dual-color colocalization analysis of the super-resolved dSTORM images revealed that the axoglial complex itself remained closely attached even under pathological conditions, but was detached from its cytoskeletal axonal anchor. Correspondingly, high-content confocal analysis of nodes of Ranvier showed that paranodal elongation occurred especially in acute and severe axonal neuropathy. Our findings show that super-resolution techniques open the possibility to identify underlying nanoscale pathology in polyneuropathies, with possible future use in diagnostic assessment.

Graphical abstract Mapping the ultrastructural organization of axoglial proteins at the node of Ranvier in nerve fibers by d STORM microscopy in health and disease. Super-resolution microscopy reveals the 190 nm periodic arrangement of structural proteins (axonal ß2-spectrin, Caspr-1 and neurofascin-155) in the healthy node of Ranvier in teased fiber preparations becoming severely disrupted in polyneuropathy patients where a loss of Caspr-1 and neurofascin-155 weakens attachment of the myelin loops. These fine periodic structures would remain hidden in conventional fluorescence microscopy. Scale bar 2 µm.

• Download figure
• Open in new tab

• Super-resolution Microscopy
• Polyneuropathy
• Node of Ranvier

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was supported by a grant of the Interdisciplinary Center of Clinical Research (IZKF) of the Medical Faculty of Würzburg to K.D. and K.G.H (F-N-439). J.L. was supported by a scholarship of the Graduate School of Life Sciences (GSLS) of the University of Würzburg. H.S.H. was supported by the Rudolf-Virchow-Center of the University of Würzburg. L.A. and K.D. hold research fellowships by the Interdisciplinary Center of Clinical Research (IZKF) of the Medical Faculty of Würzburg.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the ethical committee of the University of Würzburg (approval number 277/13 and 15/19). All subjects gave written informed consent prior to participation.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes